

Title	Human neutrophil clearance of bacterial pathogens triggers anti-microbial $\gamma\delta$ T cell responses in early infection
Authors	Davey, Martin S.;Lin, Chan-Yu;Roberts, Gareth W.;Heuston, Sinéad;Brown, Amanda C.;Chess, James A.;Toleman, Mark A.;Gahan, Cormac G.;Hill, Colin;Parish, Tanya;Williams, John D.;Davies, Simon J.;Johnson, David W.;Topley, Nicholas;Moser, Bernhard;Eberl, Matthias
Publication date	2011-05-12
Original Citation	Davey MS, Lin C-Y, Roberts GW, Heuston S, Brown AC, et al. (2011) Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial $\gamma\delta$ T Cell Responses in Early Infection. PLoS Pathog 7(5): e1002040. doi:10.1371/journal.ppat.1002040
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1002040 - 10.1371/journal.ppat.1002040
Rights	© 2011 Davey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. - http://creativecommons.org/licenses/by/2.5/
Download date	2024-05-06 13:40:53
Item downloaded from	https://hdl.handle.net/10468/850

Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial $\gamma\delta$ T Cell Responses in Early Infection

Martin S. Davey^{1,9}, Chan-Yu Lin^{1,2,9}, Gareth W. Roberts³, Sinéad Heuston⁴, Amanda C. Brown⁵, James A. Chess⁶, Mark A. Toleman¹, Cormac G. M. Gahan⁴, Colin Hill⁴, Tanya Parish⁵, John D. Williams³, Simon J. Davies⁷, David W. Johnson^{8,9}, Nicholas Topley¹, Bernhard Moser¹, Matthias Eberl^{1*}

1 Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, United Kingdom, **2** Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, **3** Institute of Nephrology, School of Medicine, Cardiff University, Cardiff, United Kingdom, **4** Alimentary Pharmabiotic Centre and Department of Microbiology, University College Cork, Cork, Ireland, **5** Centre for Immunology and Infectious Disease, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom, **6** Department of Nephrology, Morriston Hospital, Swansea, United Kingdom, **7** Department of Nephrology, University Hospital of North Staffordshire, Keele University, Stoke-on-Trent, United Kingdom, **8** Department of Nephrology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia, **9** Australia and New Zealand Dialysis Transplant Registry, University of Adelaide, Adelaide, Australia

Abstract

Human blood V γ 9/V δ 2 T cells, monocytes and neutrophils share a responsiveness toward inflammatory chemokines and are rapidly recruited to sites of infection. Studying their interaction *in vitro* and relating these findings to *in vivo* observations in patients may therefore provide crucial insight into inflammatory events. Our present data demonstrate that V γ 9/V δ 2 T cells provide potent survival signals resulting in neutrophil activation and the release of the neutrophil chemoattractant CXCL8 (IL-8). In turn, V γ 9/V δ 2 T cells readily respond to neutrophils harboring phagocytosed bacteria, as evidenced by expression of CD69, interferon (IFN)- γ and tumor necrosis factor (TNF)- α . This response is dependent on the ability of these bacteria to produce the microbial metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), requires cell-cell contact of V γ 9/V δ 2 T cells with accessory monocytes through lymphocyte function-associated antigen-1 (LFA-1), and results in a TNF- α dependent proliferation of V γ 9/V δ 2 T cells. The antibiotic fosmidomycin, which targets the HMB-PP biosynthesis pathway, not only has a direct antibacterial effect on most HMB-PP producing bacteria but also possesses rapid anti-inflammatory properties by inhibiting $\gamma\delta$ T cell responses *in vitro*. Patients with acute peritoneal-dialysis (PD)-associated bacterial peritonitis – characterized by an excessive influx of neutrophils and monocytes into the peritoneal cavity – show a selective activation of local V γ 9/V δ 2 T cells by HMB-PP producing but not by HMB-PP deficient bacterial pathogens. The $\gamma\delta$ T cell-driven perpetuation of inflammatory responses during acute peritonitis is associated with elevated peritoneal levels of $\gamma\delta$ T cells and TNF- α and detrimental clinical outcomes in infections caused by HMB-PP positive microorganisms. Taken together, our findings indicate a direct link between invading pathogens, neutrophils, monocytes and microbe-responsive $\gamma\delta$ T cells in early infection and suggest novel diagnostic and therapeutic approaches.

Citation: Davey MS, Lin C-Y, Roberts GW, Heuston S, Brown AC, et al. (2011) Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial $\gamma\delta$ T Cell Responses in Early Infection. PLoS Pathog 7(5): e1002040. doi:10.1371/journal.ppat.1002040

Editor: E. John Wherry, University of Pennsylvania, United States of America

Received: December 5, 2010; **Accepted:** March 11, 2011; **Published:** May 12, 2011

Copyright: © 2011 Davey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by Welsh Assembly Government project grants H07-03-18 (ME and NT) and HA09-009 (GWR, ME and NT) and by Baxter Healthcare Renal Discoveries extramural grant #08AP002 (ME, JDW and CYL). BM was in receipt of a Royal Society Wolfson Research Merit Award; ME was in receipt of a RCUK Fellowship in Translational Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: eberlm@cf.ac.uk

† These authors contributed equally to this work.

Introduction

The cellular immune system consists of an ‘innate’ arm of phagocytes and antigen-presenting cells, and an ‘adaptive’ arm of antigen-specific lymphocytes capable of developing immunological memory. Yet, there is increasing evidence of considerable crosstalk between the two [1]. Innate responses directly influence the shape and outcome of adaptive T cell responses, and *vice versa* specialized T cell subsets feedback to innate cells [2]. Among these interactions, the regulation of neutrophil-mediated inflammatory responses by Th17 cells has received enormous attention over the past few years [3], and with the emergence of novel T cell subsets

additional networks are being proposed so that each polarized T cell eventually pairs with an innate counter player [4–7].

The necessity to integrate complex signals in order to mount the most effective defense is best illustrated by the existence of ‘unconventional’ T cells bridging the classical divide between innate and adaptive immunity, such as natural killer T cells, mucosal-associated invariant T cells, intestinal intraepithelial CD8 $\alpha\alpha^+$ T cells and dendritic epidermal $\gamma\delta$ T cells [8–14]. These often tissue-associated lymphocytes are characterised by restricted T cell receptor (TCR) repertoires that allow them to respond rapidly to a limited range of conserved structures. Unconventional T cells readily assume a plethora of effector functions, ranging

Author Summary

The immune system of all jawed vertebrates harbors three distinct lymphocyte populations – $\alpha\beta$ T cells, $\gamma\delta$ T cells and B cells – yet only higher primates including humans possess so-called V γ 9/V δ 2 T cells, an enigmatic $\gamma\delta$ T cell subset that uniformly responds to the majority of bacterial pathogens. For reasons that are not understood, this responsiveness is absent in all other animals although they too are constantly exposed to a plethora of potentially harmful micro-organisms. We here investigated how V γ 9/V δ 2 T cells respond to live microbes by mimicking physiological conditions in acute disease. Our experiments demonstrate that V γ 9/V δ 2 T cells recognize a small common molecule released when invading bacteria become ingested and killed by other white blood cells. The stimulation of V γ 9/V δ 2 T cells at the site of infection amplifies the inflammatory response and has important consequences for pathogen clearance and the development of microbe-specific immunity. However, if triggered at the wrong time or the wrong place, this rapid reaction toward bacteria may also lead to inflammation-related damage. These findings improve our insight into the complex cellular interactions in early infection, identify novel biomarkers of diagnostic and predictive value and highlight new avenues for therapeutic intervention.

from sentinel tasks and targeted killing to engaging with keratinocytes, fibroblasts, phagocytes and antigen-presenting cells as well as other lymphocyte.

$\gamma\delta$ T cells expressing a V γ 9/V δ 2 TCR – V γ 2/V δ 2 according to an alternative nomenclature – are only found in humans and higher primates and differ fundamentally from all other conventional and unconventional T cells [15]. Activated V γ 9/V δ 2 T cells produce a range of cytokines, kill infected and transformed target cells, regulate survival and differentiation of monocytes and maturation of dendritic cells, provide B cell help and present antigens to CD4⁺ and CD8⁺ T cells [11,12,16,17]. They expand considerably in many infections, at times to >50% of all circulating T cells within a few days [18], and respond selectively in a non-MHC restricted manner to the microbial metabolite (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) [19]. HMB-PP is an intermediate of the non-mevalonate pathway of isoprenoid biosynthesis that is present in many bacteria and in malaria parasites but not in humans [17–19]. The rapid and sensitive response of V γ 9/V δ 2 T cells to a broad range of pathogens evokes cardinal features of innate immunity. Indeed, HMB-PP fulfills Janeway's criteria for a 'pathogen-associated molecular pattern' in that it is (i) invariant among different species; (ii) a product of a pathway unique to micro-organisms; and (iii) essential in microbial physiology [17]. Yet, HMB-PP recognition is not mediated *via* germline-encoded pattern recognition receptors but involves the re-arranged V γ 9/V δ 2 TCR [20–22].

Bacteria that possess the non-mevalonate pathway and hence produce HMB-PP comprise some of the most detrimental human pathogens such as the causative agents of cholera, diphtheria, plague, tuberculosis and typhoid, but also numerous commensal and opportunistic species in the mucosal flora, skin and feces [19,23]. In all these micro-organisms, HMB-PP is an essential intracellular metabolite, and it is not clear whether and how it is released by invading bacteria and becomes visible to the immune system as soluble molecule. Indeed, earlier studies with mycobacteria suggested that uptake of whole bacteria by monocytes, macrophages, or DCs may be required for the recognition by V γ 9/V δ 2 T cells [24–27]. Neutrophils are the first immune cells

infiltrating the site of infection and the main phagocytes responsible for early pathogen clearance, and growing evidence points toward a crucial role of $\gamma\delta$ T cells in regulating neutrophil responses in mouse models of infection, hypersensitivity and autoimmunity [8,12]. Yet, the interplay between $\gamma\delta$ T cells and neutrophils has not been addressed in detail [28,29]. Our present data demonstrate that V γ 9/V δ 2 T cells readily respond to neutrophils harboring phagocytosed bacteria, and that this response is strictly dependent on the ability of these bacteria to produce HMB-PP and cell-cell contact of V γ 9/V δ 2 T cells with accessory monocytes. The majority of circulating V γ 9/V δ 2 T cells shows migration properties similar to monocytes [30], suggesting that these two cell types are co-recruited to the site of inflammation and interact with each other at early stages of infection [17,31]. Our present findings thus indicate a direct link between invading pathogens, neutrophils, monocytes and microbe-responsive $\gamma\delta$ T cells, and suggest novel diagnostic and therapeutic approaches in acute infection.

Results

Human $\gamma\delta$ T cells induce neutrophil survival and activation

Neutrophils are short-lived phagocytes that undergo spontaneous apoptosis *in vitro* unless rescued by survival signals. We previously demonstrated that activated human V γ 9/V δ 2 T cells induce monocytes to survive and differentiate into inflammatory dendritic cells [31]. Here, HMB-PP stimulated V γ 9/V δ 2 T cells had a similar survival effect on autologous neutrophils and readily rescued them from undergoing apoptosis (Figure 1). This effect was selective and dependent on the number of V γ 9/V δ 2 T cells and the concentration of HMB-PP. An increase in neutrophil survival could already be observed at ratios of only 1 $\gamma\delta$ T cell per 100 neutrophils and at HMB-PP concentrations as low as 0.1–1 nM. Activation of V γ 9/V δ 2 T cells in these cultures was confirmed by upregulation of CD69 and secretion of interferon (IFN)- γ (Figure S1 in Text S1). The low $\gamma\delta$ T cell numbers and HMB-PP concentrations needed to promote neutrophil survival *in vitro* are likely to have physiologic relevance.

Activated neutrophils mobilize intracellular stores of CD11b to the cell surface and shed CD62L, thus enhancing their potential to undergo firm adhesions with endothelial cells and extravasate at the site of inflammation. In line with their anti-apoptotic effect on neutrophils, V γ 9/V δ 2 T cells induced upregulation of CD11b and loss of CD62L in surviving neutrophils in an HMB-PP dependent manner (Figure 2A). Importantly, synthetic HMB-PP alone did not have any activity on neutrophils in the absence of $\gamma\delta$ T cells (Figure 1, Figure 2 and data not shown).

Rapid recruitment of neutrophils involves the chemotactic action of CXCL8 (IL-8) produced at the site of inflammation, and increased endothelial permeability mediated by tumor necrosis factor (TNF)- α . Analysis of the supernatants from the above experiments revealed that co-cultures of neutrophils and HMB-PP stimulated V γ 9/V δ 2 T cells produced considerable amounts of both CXCL8 and TNF- α , in a dose-dependent manner and at levels comparable to lipopolysaccharide (LPS) stimulated neutrophils (Figure 2B). Another cytokine implicated in neutrophil recruitment is IL-17, which in a number of infection models is readily produced by murine $\gamma\delta$ T cells [8]. While activated V γ 9/V δ 2 T cells readily produce TNF- α , IFN- γ and granulocyte/macrophage colony-stimulating factor (GM-CSF) [31,32], we were unable to detect IL-17 in our co-cultures indicating that under the conditions tested human $\gamma\delta$ T cells failed to secrete relevant levels of IL-17 (data not shown). This is reminiscent of recent findings




Figure 1. HMB-PP stimulated V γ 9/V δ 2 T cells induce neutrophil survival. Dose-dependent survival of neutrophils incubated with LPS, and of neutrophils (PMN) co-cultured with V γ 9/V δ 2 T cells at various ratios in the presence of HMB-PP at different concentrations. Neutrophils were analyzed after 20 hours in culture; dot plots depict representative annexin-V and fixable live/dead stainings for live CD3⁺ CD15⁺ neutrophils cultured under the indicated conditions. Data shown are mean percentages (%) + SEM of live cells from independent experiments using three different donors. doi:10.1371/journal.ppat.1002040.g001

that human $\alpha\beta$ T cells including human Th17 cells modulate neutrophils (which lack the IL-17 receptor C chain) in an IL-17-independent manner through a combination of TNF- α , IFN- γ and GM-CSF [33]. In our cultures, blocking experiments demonstrated that TNF- α played a key role in the $\gamma\delta$ T cell-mediated effect on neutrophils, as judged by a partial inhibition of neutrophil survival and a reduction of CD11b expression in the presence of soluble TNF- α receptor (sTNFR), while neutralizing antibodies against GM-CSF and IFN- γ had no significant effect (Figure 3).

Taken together, these data show that V γ 9/V δ 2 T cells become activated by soluble HMB-PP in the presence of autologous neutrophils and that they provide potent stimulatory signals inducing neutrophil survival and activation. The interaction of the two cell types leads to the rapid release of the pro-inflammatory mediators CXCL8 and TNF- α into the microenvironment, thereby potentially maintaining neutrophil influx at the site of infection.

V γ 9/V δ 2 T cells respond to neutrophils harboring phagocytosed bacteria

Under physiological conditions, invading pathogens are rapidly taken up by newly recruited neutrophils. We therefore tested whether V γ 9/V δ 2 T cells respond to neutrophils harboring phagocytosed bacteria in a similar manner as they respond to soluble HMB-PP. In order to do this, we set up triple cultures consisting of neutrophils, monocytes and V γ 9/V δ 2 T cells, mimicking physiological conditions at the site of infection.

Human neutrophils readily took up green fluorescent protein (GFP) expressing *Escherichia coli*, *Listeria innocua* and *Mycobacterium smegmatis*, with >95% of the neutrophils being GFP⁺ within 30 min (Figure 4A and data not shown). Triple co-cultures of neutrophils harboring different strains of *M. smegmatis* with autologous V γ 9/V δ 2 T cells and monocytes led to rapid $\gamma\delta$ T cell activation, as evidenced by upregulation of CD69 and expression of TNF- α and IFN- γ within 20 hours (Figure 4B and data not shown). Activation profiles were similar to those seen in

control cultures with non-infected neutrophils in the presence of synthetic HMB-PP, demonstrating that V γ 9/V δ 2 T cells respond to bacterial degradation products released or presented by neutrophils. For the sake of clarity and simplicity all activation data in the following sections are shown as proportion of CD69⁺ TNF- α ⁺ $\gamma\delta$ T cells in the cultures although the cells were always co-stained for IFN- γ as well. The proportion of CD69⁺ IFN- γ ⁺ and TNF- α ⁺ IFN- γ ⁺ $\gamma\delta$ T cells followed essentially the same pattern throughout this study and led to the same conclusions.

The V γ 9/V δ 2 T cell response to phagocytosed bacteria depends on the ability of bacteria to produce HMB-PP

In order to investigate the correlation between the ability of bacteria to produce HMB-PP and their capacity to stimulate V γ 9/V δ 2 T cells, we designed experiments to distinguish a specific $\gamma\delta$ T cell response to HMB-PP from a possible background stimulation by the plethora of other microbial compounds acting *via* pattern recognition receptors. Thus, we generated a *M. smegmatis* transfectant stably expressing a second copy of the gene encoding HMB-PP synthase (*gcpE*) and hence overproducing HMB-PP compared to the parental wildtype (wt) strain [34] (Figure S2 in Text S1). As a second bacterial model we utilized HMB-PP producing and HMB-PP deficient strains of the non-pathogenic Gram-positive bacterium *Listeria innocua* [35,36] (Figure S3 in Text S1).

Compared with *M. smegmatis* wt bacteria, higher levels of V γ 9/V δ 2 T cell activation were observed when using *M. smegmatis-gcpE*⁺ (Figure 5). Furthermore, considerable V γ 9/V δ 2 T cell activation was seen with phagocytosed *L. innocua-gcpE*⁺, a strain in which HMB-PP artificially accumulates, but not with the naturally HMB-PP deficient *L. innocua* wt strain that was >100 \times less potent (Figure 5). The double transfectant *L. innocua-gcpE*⁺ *hlyB*⁺, in which HMB-PP becomes converted into the downstream reaction products isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), resulted in no detectable V γ 9/V δ 2 T cell activation (data not shown). These data demonstrate that the




Figure 2. HMB-PP stimulated $V\gamma 9/V\delta 2$ T cells induce neutrophil activation and production of pro-inflammatory mediators. (A) Dose-dependent up-regulation of CD11b and shedding of CD62L by neutrophils incubated with LPS as positive control, and of neutrophils co-cultured with $V\gamma 9/V\delta 2$ T cells at various ratios in the presence of HMB-PP at different concentrations. Neutrophils were analyzed after 20 hours in culture; histograms depict representative CD11b and CD62L stainings for live CD3⁺ CD15⁺ neutrophils cultured under the indicated conditions. Data shown are mean fluorescence intensities (MFI) + SEM from independent experiments using three different donors. (B) Dose-dependent secretion of CXCL8 and TNF- α into the culture supernatant of neutrophils incubated with LPS as positive control, and of neutrophils co-cultured with $V\gamma 9/V\delta 2$ T cells at various ratios in the presence of HMB-PP at different concentrations. Supernatants were analyzed after 20 hours by ELISA. Data shown are mean levels (pg/ml) + SEM from independent experiments using three different donors. doi:10.1371/journal.ppat.1002040.g002

response of $V\gamma 9/V\delta 2$ T cells to neutrophils harboring phagocytosed bacteria depends on the ability of these bacteria to produce HMB-PP and suggest that phagocytosis and subsequent degradation of bacteria in neutrophils leads to either presentation of




Figure 3. HMB-PP stimulated $V\gamma 9/V\delta 2$ T cells induce neutrophil survival and activation through TNF- α . Neutrophils were co-cultured with $V\gamma 9/V\delta 2$ T cells for 20 hours at a ratio of 5:1, in the absence or presence of 10 nM HMB-PP. Soluble cytokines were blocked by the addition of sTNFR, anti-GM-CSF or anti-IFN- γ . Data shown are mean values + SEM for neutrophil survival and expression of CD11b by live neutrophils, as determined in independent experiments using three different donors.

doi:10.1371/journal.ppat.1002040.g003

HMB-PP on the cell surface or the release of soluble HMB-PP into the microenvironment.

Crosstalk with monocytes provides essential help for the $V\gamma 9/V\delta 2$ T cell response to phagocytosed bacteria

$V\gamma 9/V\delta 2$ T cells, monocytes and neutrophils share a responsiveness toward inflammatory chemokines and are the earliest leukocytes recruited to sites of infection. $V\gamma 9/V\delta 2$ T cell responses *in vitro* are greatly facilitated by contact with monocytes as 'feeder cells', which most likely act by 'presenting' HMB-PP to $V\gamma 9/V\delta 2$ T cells and by providing contact-dependent signals [17]. In support of our previous observation of a substantial HMB-PP dependent crosstalk between $V\gamma 9/V\delta 2$ T cells and monocytes leading to optimum $\gamma\delta$ T cell activation [31], the response of $V\gamma 9/V\delta 2$ T cells to neutrophils harboring phagocytosed *L. innocua-gcpE*⁺ was largely dependent on the presence of monocytes. Omission of monocytes from the co-cultures resulted in greatly reduced expression levels of CD69, TNF- α and IFN- γ , compared to triple co-cultures (Figure 6A and data not shown), suggesting that monocytes provide essential help for the recognition of bacteria by $V\gamma 9/V\delta 2$ T cells and increase the sensitivity of the response especially at low HMB-PP concentrations.

We speculated that this accessory effect might have stemmed from contact-dependent interactions of monocytes with either neutrophils or $\gamma\delta$ T cells and tested this hypothesis in transwell cultures where neutrophils harboring phagocytosed *L. innocua-gcpE*⁺ in the lower chamber were separated from $V\gamma 9/V\delta 2$ T cells in the upper chamber. As shown in Figure 6B, cell-cell contact between monocytes and $V\gamma 9/V\delta 2$ T cells was crucial for the response to phagocytosed bacteria, while no contact was needed between $V\gamma 9/V\delta 2$ T cells and neutrophils, and neither between




Figure 4. V γ 9/V δ 2 T cells respond to bacteria upon phagocytosis by neutrophils. (A) Resting neutrophils or neutrophils after phagocytosis of *M. smegmatis*-gfp⁺ stably expressing GFP, at a multiplicity of infection (MOI) of 10. Cells were counter-stained with DAPI and imaged by fluorescence microscopy. Data shown are representative from independent experiments using two different donors. (B) Activation of V γ 9/V δ 2 T cells co-cultured for 20 hours with neutrophils in the absence (medium) or in the presence of 10 nM HMB-PP, or co-cultured with neutrophils harboring *M. smegmatis*-gcpE⁺ overexpressing HMB-PP synthase. Data shown are representative from independent experiments using three different donors. doi:10.1371/journal.ppat.1002040.g004

monocytes and neutrophils. These data indicate that upon phagocytosis of HMB-PP⁺ bacteria, neutrophils release soluble factors that efficiently stimulate V γ 9/V δ 2 T cells, while monocytes provide important contact-dependent accessory signals.

Upon phagocytosis of HMB-PP⁺ bacteria neutrophils release HMB-PP into the culture supernatant

Since neutrophils harboring bacteria were able to stimulate V γ 9/V δ 2 T cells in a transwell system, we next examined whether cell-free culture supernatants derived from infected neutrophils stimulated V γ 9/V δ 2 T cells in a similar manner. Indeed, V γ 9/V δ 2 T cells readily responded to supernatants from neutrophils harboring *L. innocua*-gcpE⁺ but not from neutrophils harboring *L. innocua* wt bacteria, as evidenced by expression of CD69, TNF- α




Figure 5. V γ 9/V δ 2 T cells show enhanced responses to phagocytosed bacteria that overproduce HMB-PP. Dose-dependent activation of V γ 9/V δ 2 T cells by neutrophils harboring genetically engineered transfectants of *M. smegmatis* (upper panel) or *L. innocua* (lower panel), in which HMB-PP accumulates intracellularly, compared to the parental wildtype strains (wt). Data shown are mean frequencies of CD69⁺ TNF- α ⁺ V γ 9/V δ 2 T cells \pm SEM after 20 hours in culture, as determined in independent experiments using three different donors. Error bars for MOIs depict mean values \pm SEM for the true colony-forming unit (CFU) counts of the bacterial inocula used. doi:10.1371/journal.ppat.1002040.g005

and IFN- γ (Figure 6C and data not shown). Importantly, short-term pre-treatment of *L. innocua*-gcpE⁺ supernatants with shrimp alkaline phosphatase abrogated the bioactivity on V γ 9/V δ 2 T cells completely (Figure 6C), evoking the known sensitivity of mycobacterial HMB-PP to dephosphorylation and the relative inactivity of the dephosphorylated products [37–39]. Control experiments confirmed that alkaline phosphatase affected the response of V γ 9/V δ 2 T cells to synthetic HMB-PP but not to the phosphatase-resistant diphosphonate analogue, HMB-PCP [40], demonstrating that the presence of alkaline phosphatase in the cultures had no inhibitory effect on the cells' ability to express CD69, TNF- α and IFN- γ (Figure 6D and data not shown). We conclude that upon phagocytosis of HMB-PP⁺ bacteria neutrophils release soluble HMB-PP into the microenvironment where it becomes accessible to monocytes and V γ 9/V δ 2 T cells.

The V γ 9/V δ 2 T cell response to phagocytosed bacteria is HMB-PP dependent but largely independent of other pathogen-associated molecular patterns

In order to assess the clinical relevance of our findings, we expanded our panel of bacteria by including clinical isolates of pathogens that are frequently associated with community- and hospital-acquired infections and pose serious threats to public health (Table S1 in Text S1). Of note, neutrophils harboring HMB-PP⁺ pathogens but not neutrophils harboring HMB-PP⁻ pathogens induced in V γ 9/V δ 2 T cells the co-expression of CD69, TNF- α and IFN- γ (Figure 7A and data not shown). This




Figure 6. V γ 9/V δ 2 T cells respond, in a monocyte-dependent manner, to phosphatase-sensitive molecules released from phagocytosed bacteria. (A) Activation of V γ 9/V δ 2 T cells by neutrophils harboring *L. innocua* wt or *L. innocua-gcpE⁺* bacteria, in the presence ($\gamma\delta$ -mo) or absence ($\gamma\delta$) of monocytes. Data shown are mean frequencies of CD69⁺ TNF- α ⁺ V γ 9/V δ 2 T cells + SEM after 20 hours in culture, as determined in independent experiments using three different donors. (B) Activation of V γ 9/V δ 2 T cells in the top chamber of a transwell plate separated from neutrophils (N) harboring *L. innocua-gcpE⁺* in the bottom chamber, in the presence or absence of monocytes (mo). Data shown are mean frequencies of CD69⁺ TNF- α ⁺ V γ 9/V δ 2 T cells + SEM after 20 hours in culture, as determined in independent experiments using three different donors. (C) Activation of V γ 9/V δ 2 T cells co-cultured for 20 hours with monocytes in the presence of supernatants from neutrophils harboring *L. innocua* wt or *L. innocua-gcpE⁺* bacteria that had been pretreated or not with alkaline phosphatase (AP). Data shown are representative from independent experiments using two different donors. (D) Activation of V γ 9/V δ 2 T cells co-cultured for 20 hours with monocytes in the presence of 1 nM HMB-PP or 100 μ M HMB-PCP pretreated or not with alkaline phosphatase (AP). Data shown are representative from independent experiments using two different donors.

doi:10.1371/journal.ppat.1002040.g006

response was largely independent of the presence of other pathogen-associated molecular patterns such as LPS as both Gram-negative (*Acinetobacter baumannii*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*) and Gram-positive bacteria (*M. smegmatis*) capable of producing HMB-PP stimulated V γ 9/V δ 2 T cells equally. Direct addition of alkaline phosphatase to these co-cultures abrogated the HMB-PP dependent cytokine responses, confirming soluble HMB-PP as common V γ 9/V δ 2 T cell stimulator in these species (Figure 7A, Figure S4 in Text S1). The bioactivity of culture supernatants harvested after 5 hours from neutrophils harboring the above bacteria corresponded to levels of 0.1–10 nM HMB-PP, as titrated against a HMB-PP standard (data not shown). Residual levels of CD69 expression after phosphatase treatment may have been due to incomplete degradation of HMB-PP and to indirect stimulation of V γ 9/V δ 2 T cells by other microbial compounds such as LPS acting on neutrophils or monocytes [41,42]. In contrast to HMB-PP producing species, HMB-PP deficient Gram-negative (*Chryseobacterium indologenes*) and Gram-positive bacteria (*Enterococcus faecalis*, *L. innocua*, *Staphylococcus aureus*) did not elicit V γ 9/V δ 2 T cells responses above background as demonstrated by the complete lack of TNF- α (Figure 7A, Figure S4 in Text S1) and IFN- γ (data not shown). These findings illustrate the extraordinary specificity

V γ 9/V δ 2 T cells for HMB-PP, even in the abundant presence of other microbial products and despite high levels of monocyte and/or neutrophil-derived mediators such as IL-1 β , IL-6 and CXCL8 that were present in our triple co-cultures regardless of the HMB-PP status of the phagocytosed bacteria (data not shown).

V γ 9/V δ 2 T cells proliferate in response to phagocytosed bacteria in a TCR, LFA-1 and TNF- α dependent manner

$\gamma\delta$ T cells expand rapidly in acute bacterial infections [18]. We therefore tested whether phagocytosed pathogens could induce expansion of 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled V γ 9/V δ 2 T cells. As shown in Figure 7B, V γ 9/V δ 2 T cells proliferated considerably in the presence of supernatants derived from neutrophils harboring HMB-PP⁺ *Enterobacter cloacae* but not from neutrophils harboring HMB-PP⁻ *Chryseobacterium indologenes* or *Staphylococcus aureus*. Similarly to the immediate up-regulation of CD69, TNF- α and IFN- γ , the proliferation of V γ 9/V δ 2 T cells in response to *Enterobacter cloacae* was HMB-PP dependent and could be abrogated by alkaline phosphatase. Expanding V γ 9/V δ 2 T cells also up-regulated the high affinity IL-2 receptor, CD25 (Figure 7B) and became responsive to exogenously added IL-2, which enhanced the proliferative response even further (data not shown). Blocking




Figure 7. V γ 9/V δ 2 T cells respond to HMB-PP producing Gram⁺ and Gram⁻ bacteria but not to HMB-PP deficient bacteria. (A) Dose-dependent activation of V γ 9/V δ 2 T cells by neutrophils harboring clinical isolates of a range of different bacteria: Gram⁻ HMB-PP⁺, *Enterobacter cloacae* (two different isolates tested, A and B) and *Klebsiella pneumoniae*; Gram⁻ HMB-PP⁻, *Chryseobacterium indologenes*; and Gram⁺ HMB-PP⁻, *Enterococcus faecalis* and *Staphylococcus aureus*; in the presence or absence of alkaline phosphatase (AP). Data shown are mean frequencies of CD69⁺ TNF-α⁺ V γ 9/V δ 2 T cells \pm SEM after 20 hours in culture, as determined in independent experiments using 3–5 donors. Error bars for MOIs depict mean values \pm SEM for the true CFU counts of the bacterial inocula used. (B) Proliferation after 5 days in culture and CD25 expression of CFSE-labeled V γ 9/V δ 2 T cells in response to supernatants from neutrophils harboring clinical isolates of the indicated bacteria, in the presence or absence of alkaline phosphatase (AP), soluble TNF-α receptor (sTNFR) or blocking antibodies against IFN-γ or CD11a. Data shown are representative of independent experiments using cells from at least two different donors. doi:10.1371/journal.ppat.1002040.g007

experiments demonstrated a crucial requirement of soluble and contact-dependent signals for optimum stimulation of V γ 9/V δ 2 T cells. TNF-α was recently implicated in V γ 9/V δ 2 T cell proliferation in response to IPP and IL-2 [43], and blocking of lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18) efficiently disrupted cluster formation with monocytes [31]. Here, both V γ 9/V δ 2 T cell proliferation and CD25 up-regulation in response to supernatants derived from neutrophils harboring HMB-PP⁺ *Klebsiella pneumoniae* (Figure 7B) or *Enterobacter cloacae* (data not shown) were readily inhibited by sTNFR and anti-CD11a antibodies but not by anti-IFN-γ antibodies. Finally, addition of anti-V γ 9 antibodies completely abrogated the V γ 9/V δ 2 T cell proliferation in response to HMB-PP (data not shown) and *Enterobacter cloacae* supernatants (Figure S7 in Text S1), confirming a requirement for the TCR [44]. Taken together, our findings demonstrate that V γ 9/V δ 2 T cells are rapidly activated by a broad range of HMB-PP producing pathogens, leading to TCR, LFA-1 and TNF-α dependent γδ T cell expansion.

Acute infections caused by HMB-PP producing bacteria are characterized by elevated numbers of activated γδ T cells

We next addressed whether the dichotomy between HMB-PP⁺ and HMB-PP⁻ pathogens in their potential to trigger γδ T cells *in vitro* is replicated under physiological conditions *in vivo*. As clinical correlate for HMB-PP⁺ and HMB-PP⁻ infections, we analyzed episodes of acute bacterial infections in peritoneal dialysis (PD) patients, in whom the peritoneal catheter affords continuous and non-invasive access to the inflammatory infiltrate (Table S2 in Text S1). PD-associated peritonitis is characterized by a considerable influx of neutrophils and monocytes into the peritoneal cavity [45,46], where the two cell types may become targets for local or infiltrating γδ T cells [31,47]. Here, in a total of 24 newly recruited patients examined on the first day of acute peritonitis (*i.e.* before administration of antibiotics), both the total number and the frequency of peritoneal V γ 9/V δ 2 T cells were elevated in HMB-PP⁺ infections compared to HMB-PP⁻ infections, suggesting increased recruitment and/or proliferation in response to

HMB-PP released by bacteria (Figure 8). Moreover, local activation was evidenced by higher percentages of V γ 9/V δ 2 T cells expressing CD69 in the HMB-PP⁺ patient group. In contrast, we did not see any significant differences in the numbers and frequencies of peritoneal neutrophils, monocytes/macrophages and total CD3⁺ T cells, regardless of the HMB-PP status of the causative pathogen (Figure S5 in Text S1). Similarly, while the proportion of V γ 9/V δ 2 T cells within peritoneal CD3⁺ T cells was clearly elevated in HMB-PP⁺ infections, CD4⁺ and CD8⁺ T cells showed no such bias (Figure S6 in Text S1).

Episodes of peritonitis caused by HMB-PP producing bacteria are associated with poor clinical outcome

As Medzhitov stated recently, “inflammation is beneficial in appropriate amounts but can easily become detrimental when excessive because of its tissue-damaging potential” [48]. PD patients constitute a particularly vulnerable group where inflammatory events can have profound consequences [49–51]. We speculated that local activation of $\gamma\delta$ T cells may contribute to inflammation-related damage and tested whether the occurrence of clinical complications in PD patients depends on the capacity of the causative pathogen to produce HMB-PP. Our analysis of 26 patients treated at the University Hospital of Wales, Cardiff, UK, demonstrated that infections with HMB-PP⁺ bacteria were associated with worse outcomes, evidenced as higher mortality rates and higher incidences of technique failure (*i.e.*, cessation of therapy due to catheter removal, transfer to hemodialysis or patient death), while HMB-PP[−] bacteria caused milder disease (Figure 9). Of note, we were able to validate this pattern in two larger and entirely independent cohorts treated in Australia (ANZDATA Registry) and at the University Hospital of North Staffordshire, Stoke-on-Trent, UK (Figure 9). In order to rule out that this pattern was not due to differences in Gram staining (and




Figure 8. V γ 9/V δ 2 T cell numbers and CD69 expression are elevated in acute peritonitis caused by HMB-PP bacteria. Total numbers and frequencies of V γ 9/V δ 2 T cells (% of total cells and % of all CD3⁺ T cells), and expression of CD69 on peritoneal V γ 9/V δ 2 T cells in patients with PD-associated peritonitis on day 1 (the day of hospital admission with a cloudy effluent, *i.e.* before commencement of antibiotic therapy), depending on whether or not the causative pathogen was capable of producing HMB-PP. doi:10.1371/journal.ppat.1002040.g008




Figure 9. Episodes of peritonitis caused by HMB-PP producing bacteria are associated with poor clinical outcome. Cumulative patient survival (*left*) and cumulative technique survival (*right*) of patients with acute bacterial peritonitis, grouped into infections with Gram⁺ HMB-PP[−] (blue), Gram⁺ HMB-PP⁺ (red) or Gram[−] HMB-PP⁺ pathogens (green); episodes caused by Gram[−] HMB-PP[−] pathogens were not recorded in the patient databases. *Top*, PD patients admitted at the University Hospital of Wales, Cardiff, with acute peritonitis (day 1, *i.e.* first presentation with a cloudy bag). *Middle*, Australian PD patients from the ANZDATA registry with first-time peritonitis. *Bottom*, PD patients with first-time peritonitis treated at the University Hospital of North Staffordshire, Stoke-on-Trent, UK. Comparisons were made using log-rank tests. doi:10.1371/journal.ppat.1002040.g009

hence endotoxin-related), we divided the group of HMB-PP⁺ bacteria further into Gram⁺ and Gram[−] species. Our outcome analysis demonstrates that even within the Gram⁺ group, bacteria capable of producing HMB-PP were associated with worse outcomes compared to HMB-PP[−] pathogens (Figure 9), suggesting that the HMB-PP producing capacity of the causative pathogen might be of predictive value for the clinical outcome from bacterial peritonitis (Table S3 in Text S1).

Peritoneal $\gamma\delta$ T cell frequencies and TNF- α levels might predict clinical outcome in peritonitis patients

In order to identify potentially useful diagnostic and prognostic biomarkers of inflammation severity and outcomes from bacterial infection, we measured a large number of immunological parameters. These analyses identified elevated frequencies of peritoneal V γ 9/V δ 2 T cells on day 1 as possible predictor of subsequent technique failure within three months after infection

Table 1. Identification of immune markers of possible predictive value for clinical outcome in 8 stable PD patients and 29 PD patients with acute peritonitis (means \pm SD).

90 th day technique failure	Stable patients	Survivors	Non-survivors
V γ 9 ⁺ (% of CD3 ⁺ T cells)	1.5 \pm 0.9	2.5 \pm 2.1	4.9 \pm 3.2*
TNF- α (pg/ml)	3.1 \pm 4.3	41.9 \pm 53.3	128.4 \pm 91.0*
90 th day mortality			
HLA-DR ⁺ (% of V δ 2 ⁺ T cells)	14.7 \pm 10.5	11.5 \pm 10.5	40.6 \pm 7.5***
TNF- α (pg/ml)	3.1 \pm 4.3	48.1 \pm 60.4	148.7 \pm 90.2*

Asterisks indicate significant differences between survivors and non-survivors.
doi:10.1371/journal.ppat.1002040.t001

(Table 1). Similarly, expression of the activation marker HLA-DR by peritoneal V γ 9/V δ 2 T cells on the day of admission was associated with increased mortality. No other parameters tested including the numbers and frequencies of neutrophils, monocytes or CD4⁺ and CD8⁺ T cells reached statistical significance (data not shown). Among soluble factors in peritoneal effluent, only elevated levels of TNF- α on day 1 indicated higher rates of technique failure and mortality (Table 1), while no such correlation was seen for other cytokines and chemokines, including GM-CSF, IFN- γ , IL-1 β , IL-2, IL-6, IL-10, IL-12p70, IL-17, IL-22, CXCL8, CXCL10 and sIL-6R (data not shown).

Pre-treatment of bacteria with fosmidomycin blocks HMB-PP production and abrogates $\gamma\delta$ T cell responses

Our findings of a rapid $\gamma\delta$ T cell response to neutrophil-engulfed HMB-PP producing pathogens and its potential detrimental consequence in episodes of acute peritonitis may not only be of diagnostic and predictive value for affected patients, they also highlight possible new avenues of therapeutic intervention in bacterial infections. HMB-PP is an intermediate of the non-mevalonate pathway of isoprenoid biosynthesis, in which the first enzymatic step catalyzed by 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr) can be inhibited by fosmidomycin (Figure S8A in Text S1), a natural antibiotic produced by *Streptomyces lavendulae* [52,53]. We therefore speculated that the effect of fosmidomycin pre-treatment of bacteria may serve a dual purpose in treating acute infections: by directly inhibiting an essential pathway in a broad range of pathogens and by abrogating HMB-PP driven inflammatory responses.

Tests with selected clinical isolates of common pathogens demonstrated that the majority of HMB-PP⁺ bacteria (*Enterobacter cloacae*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*) was susceptible to overnight treatment with fosmidomycin (with the exception of *Acinetobacter baumannii* as expected [54]), with a mean inhibitory concentration (MIC) of 1–32 μ g/ml depending on the strain (Table S1 in Text S1). Of note, fosmidomycin also acted on multidrug-resistant strains including bacteria harboring the recently discovered ‘New Delhi’ metallo- β -lactamase 1 (NDM-1) [55,56] (Davey MS, Tyrrell JM *et al.*, submitted for publication). In contrast to the efficient killing of most HMB-PP⁺ bacteria, the HMB-PP[−] bacteria *Chryseobacterium indologenes*, *Enterococcus faecalis* and *Staphylococcus aureus* were not affected by fosmidomycin (Table S1 in Text S1).

We next investigated the potential of short-term fosmidomycin treatment to affect $\gamma\delta$ T cell activation by inhibiting the bacterial HMB-PP biosynthesis. Prior exposure of bacteria to fosmidomycin

for 1 hour did not affect uptake by neutrophils as demonstrated using *Escherichia coli-gfp*⁺ (Figure S8B in Text S1), and neither did it affect gross bacterial viability as confirmed by re-plating treated *Enterobacter cloacae* on antibiotic-free plates in order to overcome the competitive inhibition by fosmidomycin (Figure 10A). Yet, pre-incubation of *Escherichia coli*, *Enterobacter cloacae* and *Klebsiella pneumoniae* with fosmidomycin for only 1 hour prior to phagocytosis by neutrophils clearly abrogated their capacity to stimulate V γ 9/V δ 2 T cells. This inhibitory effect on $\gamma\delta$ T cell responses was evident both for activation of V γ 9/V δ 2 T cells in triple co-cultures with neutrophils harboring fosmidomycin-treated bacteria (Figure 10A and data not shown) as well as for activation (Figure S8B in Text S1) and proliferation (Figure 10B) of V γ 9/V δ 2 T cells in response to cell-free supernatants from neutrophils harboring fosmidomycin-treated bacteria. Together these results indicate that fosmidomycin not only has a direct antibacterial effect but also possesses immediate anti-inflammatory properties by inhibiting $\gamma\delta$ T cell-driven responses (Figure 11), thus making the non-mevalonate pathway an attractive novel drug target for the treatment of acute infection.




Figure 10. Abrogation of HMB-PP dependent $\gamma\delta$ T cell responses by fosmidomycin. (A) Activation of V γ 9/V δ 2 T cells co-cultured for 20 hours with neutrophils harboring *Enterobacter cloacae* pre-treated or not for 1 hour with the indicated concentrations of fosmidomycin. The minimum inhibitory concentration (MIC) of fosmidomycin for this bacteria strain was 1 μ g/ml, as determined by microbroth dilution (Table S1 in Text S1). Data shown are frequencies of CD69⁺ TNF- α ⁺ V γ 9/V δ 2 T cells after 20 hours in culture, alongside CFU counts of the original bacterial inocula after 1 hour treatment with fosmidomycin, representative of independent experiments using cells from two different donors. FACS plots show typical V γ 9/V δ 2 T cell responses, representative of independent experiments using cells from three different donors. (B) Proliferation after 5 days in culture of CFSE-labeled V γ 9/V δ 2 T cells in response to supernatants from neutrophils harboring *Enterobacter cloacae* pre-treated or not for 1 hour with 0.25 μ g/ml fosmidomycin. Data shown are representative of independent experiments using cells from two different donors.
doi:10.1371/journal.ppat.1002040.g010

microbial compounds such as LPS. This is in stark contrast to other cytokines produced by innate immune cells such as IFN- α and IFN- β which may induce upregulation of CD69 on V γ 9/V δ 2 T cells but fail to co-stimulate V γ 9/V δ 2 T cell proliferation [32]. Taken together, we identified an inflammatory crosstalk of V γ 9/V δ 2 T cells, neutrophils and monocytes in the presence of HMB-PP producing bacteria that can be manipulated at various checkpoints: (i) the antibiotic fosmidomycin abrogates the microbial HMB-PP production and thus renders bacterial pathogens invisible for V γ 9/V δ 2 T cells; (ii) alkaline phosphatase degrades free HMB-PP released by neutrophils into the microenvironment; (iii) blocking antibodies against the TCR prevent the recognition of HMB-PP by V γ 9/V δ 2 T cells; (iv) blocking antibodies against CD11a disrupt the LFA-1/ICAM-1 dependent contact between $\gamma\delta$ T cells and monocytes needed for $\gamma\delta$ T cell stimulation; (v) and sTNFR neutralizes soluble TNF- α which is released by all three cell types in response to microbial ligands and acts as growth factor for V γ 9/V δ 2 T cells and survival factor for neutrophils (Figure 11).

How does the HMB-PP dependent crosstalk of V γ 9/V δ 2 T cells, monocytes and neutrophils *in vitro* translate into the situation *in vivo* in acutely infected patients? Studies in patients with systemic inflammatory response syndrome suggested a significant role for V γ 9/V δ 2 T cells as early responders after severe insult and identified a correlation between V γ 9/V δ 2 T cell activation and clinical scores [67]. Our own findings in patients with PD-related peritonitis support this notion and demonstrate that the capacity of the causative pathogen to produce HMB-PP and local infiltrates of activated V γ 9/V δ 2 T cells on day 1 are indicative of acute inflammatory responses and may predict the subsequent clinical outcome from infection. It is becoming increasingly clear that the nature of the infection is a major determinant of outcome, and future interventions may well have to focus on subgroups of patients with different forms of infection [68]. A careful re-analysis of peritonitis outcomes from validated registry data [69–76] confirms that HMB-PP⁺ bacteria cause clinically more severe infection and emphasizes the need to pay more attention to detailed host-pathogen interactions. Bacterial infection remains a leading cause of morbidity and mortality worldwide, not the least due to the alarming spread of antibiotic-resistant pathogens that is posing an enormous challenge on clinical practice, public healthcare and biomedical research [55,56]. In most cases, antimicrobial treatment is largely empirical as microbiological culture results are typically not available for 2–3 days. Moreover, many times no organism can be identified, with rates of culture-negative infections occasionally reaching 50% [77]. In contrast, laboratory analyses of immune cells and/or soluble mediators may provide valuable information within a few hours and both aid diagnosis and refine treatment. In this respect, fosmidomycin or related HMB-PP inhibitors might constitute useful combination partners for antibiotic therapy especially in critical cases such as acute peritonitis or sepsis where the intervention has to commence before the nature of the causative pathogen is known, and where activated V γ 9/V δ 2 T cells may contribute to poor clinical outcome. Fosmidomycin targets an essential pathway in a broad range of pathogens [54,78,79] and simultaneously abrogates V γ 9/V δ 2 T cell responses [80,81]. Of note, the inhibitory effect of fosmidomycin on the V γ 9/V δ 2 T cell bioactivity was detectable after only 1 hour of treatment and well below its MIC, *i.e.* under conditions that would easily be achievable in patients. Other ways of specifically manipulating $\gamma\delta$ T cell mediated responses may include the use of anti- $\gamma\delta$ TCR antibodies or $\gamma\delta$ TCR antagonists such as BrH-PCP [82]. Given the importance of TNF- α for $\gamma\delta$ T cell proliferation and the association of peritoneal TNF- α levels with morbidity and mortality, one may also advocate the use of

TNF- α blocking reagents for the treatment of acute PD-related peritonitis [83].

Taken together our experiments demonstrate that V γ 9/V δ 2 T cells recognize with HMB-PP a small common molecule released by the majority of invading bacteria when they become phagocytosed by neutrophils. Stimulation of V γ 9/V δ 2 T cells at the site of infection is likely to amplify the local inflammatory response with important consequences for pathogen clearance and the development of microbe-specific immunity. However, if triggered at the wrong time or the wrong place, this rapid reaction toward most bacteria may also lead to inflammation-related damage and detrimental clinical outcome. These findings improve our insight into the complex cellular interactions in early infection, identify novel biomarkers of possible diagnostic and predictive value and highlight new avenues for therapeutic intervention.

Materials and Methods

Ethics statement

This study was conducted according to the principles expressed in the Declaration of Helsinki and under local ethical guidelines (Bro Taf Health Authority, Wales). The study was approved by the South East Wales Local Ethics Committee under reference number 04WSE04/27. All patients provided written informed consent for the collection of samples and subsequent analysis.

Patients

The Cardiff study population included 39 adult patients who were receiving PD at the University Hospital of Wales, Cardiff, UK, and were admitted with acute peritonitis between September 2008 and October 2010 (Table S2 in Text S1). Eight stable patients with no infection in the previous 3 months were included in this study as non-infected controls. In addition, microbiological and survival data were obtained from all 739 adult patients who were receiving PD between 1987 and 2008 at the University Hospital of North Staffordshire, Stoke-on-Trent, UK; and from all 2,542 Australian adult patients from the Australia and New Zealand Dialysis Transplant (ANZDATA) Registry who were receiving PD between 2003 and 2008 (Table S2 in Text S1). Diagnosis of acute peritonitis was based on the presence of abdominal pain and cloudy peritoneal effluent with >100 WBC/ mm^3 . Infections were grouped into culture-positive and culture-negative episodes, according to the result of the microbiological analysis of the effluent. Bacteria species identified in culture-positive infections were grouped into HMB-PP⁺ and HMB-PP[−], based on the presence or absence of HMB-PP in the microbial metabolism [17,19]. Endpoints of outcome analyses were 14th and 90th day mortality and technique failure (catheter removal, transfer to hemodialysis, and/or patient death). In order to rule out a history of previous antibiotic treatment as a potentially confounding factor, outcome studies were restricted to patients with first-episode peritonitis, excluding cases of fungal infection or unrecorded culture results.

Bacteria culture

Bacteria strains used in this study are listed in Table S1 in Text S1. *Mycobacterium smegmatis* strains were grown aerobically at 37°C in liquid Lemco medium (Oxoid) supplemented with 10 mg/ml peptone, 5 mg/ml NaCl and 0.25% Tween 80 (Sigma), or on solid Lemco plates with 15 mg/ml agar (Fisher). *Listeria innocua* strains were grown aerobically at 37°C in liquid brain heart infusion medium (Oxoid) or on agar plates. *Escherichia coli* laboratory strains and multi-drug resistant clinical isolates of *Acinetobacter baumannii*,

Chryseobacterium indologenes, *Enterobacter cloacae*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* were grown in liquid LB broth and on solid Columbia blood agar (Oxoid). Where appropriate, antibiotics were added to the medium: *M. smegmatis-gcpE⁺*, 100 µg/ml hygromycin B; *L. innocua-gcpE⁺*, 7.5 µg/ml chloramphenicol; *E. coli-gfp⁺*, 100 µg/ml ampicillin (all from Sigma). Bacterial susceptibilities to fosmidomycin were determined by microbroth dilution method, according to the Clinical and Laboratory Standards Institute guidelines [84]. A log 2 dilution series of 0.06 to 128 µg/ml allowed the identification of the minimal inhibitory concentration (MIC) where bacterial growth was absent. No defined break points have been acknowledged for fosmidomycin [85], therefore resistance was defined as concentrations >128 µg/ml.

Cell isolation

Peritoneal cells were harvested from chilled overnight dwell effluents [31,47]; cell-free supernatants were stored at -70°C. PBMC were isolated from peripheral blood of healthy volunteers using Lymphoprep (Axis-Shield). Vγ9⁺ T cells (>98%) were purified from PBMC using monoclonal antibodies (mAbs) against Vγ9-PE-Cy5 (Immu360; Beckman-Coulter) and anti-PE microbeads (Milenyi). Monocytes (>98%) were purified using anti-CD14 microbeads (Milenyi). Neutrophils (>95%) used for bacterial phagocytosis were isolated from peripheral blood using a Lymphoprep gradient followed by dextran sedimentation [86]. Remaining erythrocytes were lysed with ammonium chloride solution (150 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA), and neutrophils were washed in HBSS without Mg²⁺ and Ca²⁺ (Sigma) and resuspended to a final cell concentration of 2×10⁶/ml in HBSS with Mg²⁺ and Ca²⁺ (Sigma) supplemented with 10% human serum. Neutrophils (>98%) used in Vγ9/Vδ2 T cell co-culture experiments were isolated from peripheral blood by initial dextran sedimentation followed by centrifugation through discontinuous Percoll gradients [87]. The cell culture medium used throughout this study was RPMI-1640 with 2 mM L-glutamine, 1% sodium pyruvate, 50 µg/ml penicillin/streptomycin and 10% fetal calf serum (Invitrogen).

Phagocytosis of live bacteria

Single colonies were grown in culture broth for 18 hours, and bacteria were washed in PBS and resuspended in HBSS with Mg²⁺ and Ca²⁺ supplemented with 10% human serum. Freshly isolated neutrophils were incubated with bacteria at a multiplicity of infection (MOI) of 0.1–100 bacteria per neutrophil for 30–60 min at 37°C, with gentle shaking. In some experiments, bacteria were pre-treated with 0.5–25 µg/ml fosmidomycin for 1 hour prior to phagocytosis. Actual MOIs of all bacterial inocula used were determined by plating out serial dilutions on agar plates and expressed as colony forming units (CFU) per neutrophil. Non-phagocytosed bacteria were washed off three times. For microscopic analyses, neutrophils harboring GFP-expressing bacteria were washed, counterstained with DAPI (Sigma) and fixed in 2% paraformaldehyde. Images were acquired on a Nikon Eclipse 80i fluorescence microscope equipped with a Nikon DXM 1200F camera and processed with Adobe Photoshop. For the generation of cell-free supernatants, neutrophils pre-incubated with bacteria as described above were cultured for 5 hours in complete RPMI-1640. Supernatants were then harvested and cells removed by centrifugation at 12,000 *g* for 10 min. Samples were stored at -20°C and thawed a maximum of 5 times. For some experiments, neutrophil supernatants were treated with 0.015 U/µl shrimp alkaline phosphatase for 30 min at 37°C.

Triple co-cultures of neutrophils, monocytes and γδ T cells

Unless indicated otherwise, neutrophils were co-cultured for 20 hours in complete RPMI-1640 medium (further supplemented with 8 µg/ml colistin (Sigma) for assays involving multi-drug resistant clinical isolates) with autologous monocytes and γδ T cells at a ratio of 10 neutrophils and 1 monocyte per 1 γδ T cell (10:1:1), in the absence or presence of 0.015 U/µl shrimp alkaline phosphatase (Roche). Proliferation assays using γδ T cells that had been pre-labeled with CFSE (Molecular Probes) were incubated for 4–6 days. Controls included co-cultures in the absence or presence of 1–100 nM synthetic HMB-PP [40] or 1–100 ng/ml LPS from *Salmonella abortus equi* (Sigma). In transwell experiments, neutrophils were separated from γδ T cells by 0.4 µm pore polycarbonate membranes (Fisher Scientific). Cell-free supernatants derived from neutrophils after phagocytosis of bacteria were tested in monocyte-γδ T cell co-cultures (1:1) at a dilution of 1 in 3. Blocking reagents used were anti-IFN-γ (25718; R&D Systems); anti-CD11a (TS1/22) from Dr Ruggero Pardi (DIBIT-Scientific Institute San Raffaele, Milano, Italy); and sTNFR p75-IgG1 fusion protein (Enbrel; Amgen); alone or in combination at 10 µg/ml each. Anti-TCR-Vγ9 (Immu360; Beckman Coulter) was used at 1.25 µg/ml.

Flow cytometry

Cells were acquired on an eight-color FACSCanto II (BD Biosciences) and analyzed with FloJo 7.6 (TreeStar), using monoclonal antibodies against CD3 (UCHT1), CD15 (HI98), CD25 (M-A251), CD62L (DREG-56), CD69 (FN50), CD86 (2331) and HLA-DR (L243) from BD Biosciences; TCR-Vγ9 (Immu360) and CD40 (mAB89) from Beckman Coulter; and CD11b (ICRF44) and CD14 (61D3) from eBioscience; together with appropriate isotype controls. Cells of interest were gated based on their appearance in side scatter and forward scatter area/height, exclusion of live/dead staining (fixable Aqua; Invitrogen) and surface staining: CD3⁺ CD14⁺ CD15⁺ neutrophils, CD3⁺ CD14⁺ CD15⁺ monocytes, and CD3⁺ Vγ9⁺ γδ T cells. Apoptotic cells were identified using Annexin V (BD Biosciences). For detection of intracellular cytokines, 10 µg/ml brefeldin A (Sigma) was added to cultures 5 hours prior to harvesting. Surface-stained cells were labeled using the Fix & Perm kit (eBioscience) and monoclonal antibodies against IFN-γ (45.15; BD Biosciences) and TNF-α (188; Beckman Coulter).

Culture supernatants and effluent samples

Soluble cytokines in cell culture supernatants were detected using ELISA kits for IL-1β, IL-6 and IL-17 (R&D Systems); and IFN-γ, TNF-α and CXCL8 (BD Biosciences). All samples were measured in duplicate on a Dynex MRX II reader. Cell-free peritoneal effluents were analyzed on a SECTOR Imager 600 (Meso Scale Discovery) for TNF-α, GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-10, IL-12p70, CXCL8 (IL-8) and soluble IL-6 receptor (sIL-6R). In addition, IL-17, IL-22 and CXCL10 in peritoneal effluents were measured in duplicate on a Dynex MRX II reader, using conventional kits (R&D Systems).

Statistical analysis

Data were analyzed using two-tailed Student's *t*-tests (GraphPad Prism 4.0), and considered significant as indicated in the figures and tables: *, *p*<0.05; **, *p*<0.01; ***, *p*<0.001. Cumulative survival curves as a function of time were generated using the Kaplan-Meier approach and compared using the log rank test (SPSS 16.0).

Supporting Information

Text S1 Supporting information.
(PDF)

Acknowledgments

We appreciate the invaluable contributions of the nephrology community who provide information to, and maintain, the ANZDATA and Stoke-on-Trent databases; this includes physicians, surgeons, nurses, renal technicians, database managers, and most importantly, the patients. We are especially grateful to all patients and healthy volunteers in Cardiff for participating in the immunological study, and the staff on the B5 ward for

their cooperation. We also thank Hassan Jomaa for providing synthetic HMB-PP and HMB-PCP; Ruggero Pardi for anti-CD11a blocking antibodies; Ann Kift-Morgan for technical assistance; and Eric Champagne, Massimo Massaia, Eric Oldfield, Chiara Riganti and Tim Walsh for the stimulating discussion.

Author Contributions

Conceived and designed the experiments: NT BM ME. Performed the experiments: MSD CYL. Analyzed the data: MSD CYL JAC BM ME. Contributed reagents/materials/analysis tools: GWR SH ACB MAT CGMG CH TP JDW SJD DWJ. Wrote the paper: BM ME.

References

- Nathan N (2006) Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* 6: 173–182.
- Müller I, Munder M, Kropf P, Hänsch GM (2009) Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? *Trends Immunol* 30: 522–530.
- Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol* 25: 821–852.
- Sallusto F, Lanzavecchia A (2009) Heterogeneity of CD4⁺ memory T cells: functional modules for tailored immunity. *Eur J Immunol* 39: 2076–2082.
- Annunziato F, Romagnani S (2009) Heterogeneity of human effector CD4⁺ T cells. *Arthritis Res Ther* 11: 257.
- Murphy KM, Stockinger B (2010) Effector T cell plasticity: flexibility in the face of changing circumstances. *Nat Immunol* 11: 674–680.
- O'Shea JJ, Paul WE (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4⁺ T cells. *Science* 327: 1098–1102.
- Hayday AC (2009) $\gamma\delta$ T cells and the lymphoid stress-surveillance response. *Immunity* 31: 184–196.
- Münz C, Steinman RM, Fujii S (2005) Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. *J Exp Med* 202: 203–207.
- Pennington DJ, Vermijlen D, Wise EL, Clarke SL, Tigelaar RE, et al. (2005) The integration of conventional and unconventional T cells that characterizes cell-mediated responses. *Adv Immunol* 87: 27–59.
- Moser B, Eberl M (2007) $\gamma\delta$ T cells: novel initiators of adaptive immunity. *Immunol Rev* 215: 89–102.
- Bonneville M, O'Brien RL, Born WK (2010) $\gamma\delta$ T cell effector functions: a blend of innate programming and acquired plasticity. *Nat Rev Immunol* 10: 467–478.
- Godfrey DI, Rossjohn J, McCluskey J (2010) Fighting infection with your MAITs. *Nat Immunol* 11: 693–695.
- De Santo C, Arscott R, Booth S, Karydis I, Jones M, et al. (2010) Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. *Nat Immunol* 11: 1039–1046.
- Hayday AC (2000) $\gamma\delta$ cells: a right time and a right place for a conserved third way of protection. *Annu Rev Immunol* 18: 975–1026.
- Holtmeier W, Kabelitz D (2005) $\gamma\delta$ T cells link innate and adaptive immune responses. *Chem Immunol Allergy* 86: 151–183.
- Eberl M, Moser B (2009) Monocytes and $\gamma\delta$ T cells: close encounters in microbial infection. *Trends Immunol* 30: 562–568.
- Morita CT, Jin C, Sarikonda G, Wang H (2007) Nonpeptide antigens, presentation mechanisms, and immunological memory of human V γ 2V δ 2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. *Immunol Rev* 215: 59–76.
- Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, et al. (2003) Microbial isoprenoid biosynthesis and human $\gamma\delta$ T cell activation. *FEBS Lett* 544: 4–10.
- Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, et al. (1995) V γ 2V δ 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. *J Immunol* 154: 998–1006.
- Evans PS, Enders PJ, Yin C, Ruckwardt TJ, Malkovsky M, et al. (2001) In vitro stimulation with a non-peptide alkylphosphate expands cells expressing V γ 2-J γ 1.2/V δ 2 T-cell receptors. *Immunology* 104: 19–27.
- Spencer CT, Abate G, Blazevic A, Hofst DF (2008) Only a subset of phosphoantigen-responsive $\gamma\delta$ 2 T cells mediate protective tuberculosis immunity. *J Immunol* 181: 4471–4484.
- Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, et al. (2006) Metagenomic analysis of the human distal gut microbiome. *Science* 312: 1355–1359.
- Dieli F, Troye-Blomberg M, Ivanyi J, Fournié JJ, Bonneville M, et al. (2000) V γ 9/V δ 2 T lymphocytes reduce the viability of intracellular *Mycobacterium tuberculosis*. *Eur J Immunol* 30: 1512–1519.
- Rojas RE, Torres M, Fournié JJ, Harding CV, Boom WH (2002) Phosphoantigen presentation by macrophages to *Mycobacterium tuberculosis*-reactive V γ 9V δ 2⁺ T cells: modulation by chloroquine. *Infect Immun* 70: 4019–4027.
- Devilder MC, Maillat S, Bouyge-Moreau I, Donnadié E, Bonneville M, et al. (2006) Potentiation of antigen-stimulated V γ 9V δ 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. *J Immunol* 176: 1386–1393.
- Wei H, Huang D, Lai X, Chen M, Zhong W, et al. (2008) Definition of APC presentation of phosphoantigen (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to V γ 2V δ 2 TCR. *J Immunol* 181: 4798–4806.
- Hirsh MI, Hashiguchi N, Chen Y, Yip L, Junger WG (2006) Surface expression of HSP72 by LPS-stimulated neutrophils facilitates $\gamma\delta$ cell-mediated killing. *Eur J Immunol* 36: 712–721.
- Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, et al. (2009) Activated V γ 9V δ 2 T cells trigger granulocyte functions via MCP-2 release. *J Immunol* 182: 522–529.
- Brandes M, Willmann K, Lang AB, Nam KH, Jin C, et al. (2003) Flexible migration program regulates $\gamma\delta$ T-cell involvement in humoral immunity. *Blood* 101: 3693–3701.
- Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, et al. (2009) A rapid crosstalk of human $\gamma\delta$ T cells and monocytes drives the acute inflammation in bacterial infections. *PLoS Pathog* 5: e1000308.
- Vermijlen D, Ellis P, Langford C, Klein A, Engel R, et al. (2007) Distinct cytokine-driven responses of activated blood $\gamma\delta$ T cells: insights into unconventional T cell pleiotropy. *J Immunol* 178: 4304–4314.
- Pelletier M, Maggi E, Micheletti A, Lazzeri E, Tamassia N, et al. (2010) Evidence for a cross-talk between human neutrophils and Th17 cells. *Blood* 115: 335–343.
- Brown AC, Eberl M, Crick DC, Jomaa H, Parish T (2010) The non-mevalonate pathway of isoprenoid biosynthesis in *Mycobacterium tuberculosis* is essential and transcriptionally-regulated by Dxs. *J Bacteriol* 192: 2424–2433.
- Begley M, Gahan CG, Kollas AK, Hintz M, Hill C, et al. (2004) The interplay between classical and alternative isoprenoid biosynthesis controls $\gamma\delta$ T cell bioactivity of *Listeria monocytogenes*. *FEBS Lett* 561: 99–104.
- Begley M, Bron PA, Heuston S, Casey PG, Englert N, et al. (2008) Analysis of the isoprenoid biosynthesis pathways in *Listeria monocytogenes* reveals a role for the alternative 2-C-methyl-D-erythritol 4-phosphate pathway in murine infection. *Infect Immun* 76: 5392–5401.
- Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. (1994) Stimulation of human $\gamma\delta$ T cells by nonpeptide mycobacterial ligands. *Science* 264: 267–270.
- Tanaka Y, Sano S, Nieves E, de Libero G, Rosa D, et al. (1994) Nonpeptide ligands for human $\gamma\delta$ T cells. *Proc Natl Acad Sci USA* 91: 8175–8179.
- Amslinger S, Hecht S, Rohdich F, Eisenreich W, Adam P, et al. (2007) Stimulation of V γ 9/V δ 2 T-lymphocyte proliferation by the isoprenoid precursor, (*E*)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate. *Immunobiology* 212: 47–55.
- Reichenberg A, Hintz M, Kleitschek Y, Kuhl T, Haug C, et al. (2003) Replacing the pyrophosphate group of HMB-PP by a diphosphate function abrogates its potential to activate human $\gamma\delta$ T cells but does not lead to competitive antagonism. *Bioorg Med Chem Lett* 13: 1257–1260.
- Eberl M, Jomaa H, Hayday AC (2004) Integrated immune responses to infection – cross-talk between human $\gamma\delta$ T cells and dendritic cells. *Immunology* 112: 364–368.
- Devilder MC, Allain S, Dousset C, Bonneville M, Scotet E (2009) Early triggering of exclusive IFN- γ responses of human V γ 9V δ 2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. *J Immunol* 183: 3625–3633.
- Li H, Luo K, Pauza CD (2008) TNF- α is a positive regulatory factor for human V γ 2V δ 2 T cells. *J Immunol* 181: 7131–7137.
- Wang H, Fang Z, Morita CT (2010) V γ 2V δ 2 T cell receptor recognition of prenyl pyrophosphates is dependent on all CDRs. *J Immunol* 184: 6209–6222.
- Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, et al. (2001) IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. *Immunity* 14: 705–714.
- McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, et al. (2003) Interplay between IFN- γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. *J Clin Invest* 112: 598–607.
- Roberts GW, Baird D, Gallagher K, Jones RE, Pepper CJ, et al. (2009) Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysis. *J Am Soc Nephrol* 20: 1895–1900.

48. Medzhitov R (2010) Inflammation 2010: new adventures of an old flame. *Cell* 140: 771–776.
49. Davies SJ, Bryan J, Phillips L, Russell GI (1996) Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. *Nephrol Dial Transplant* 11: 498–506.
50. Topley N (1998) Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. *Adv Ren Replace Ther* 5: 179–184.
51. Devuyst O, Margetts PJ, Topley N (2010) The pathophysiology of the peritoneal membrane. *J Am Soc Nephrol* 21: 1077–1085.
52. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, et al. (1999) Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. *Science* 285: 1573–1576.
53. Missinou MA, Borrmann S, Schindler A, et al. (2002) Fosmidomycin for malaria. *Lancet* 360: 1941–1942.
54. Neu Y, Kamimura T (1981) *In vitro* and *in vivo* antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent. *Antimicrob Agents Chemother* 19: 1013–1023.
55. Walsh TR, Toleman MA, Poirel L, Nordmann P (2005) Metallo- β -lactamases: the quiet before the storm? *Clin Microbiol Rev* 18: 306–325.
56. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 10: 597–602.
57. Jomaa H, Feurle J, Lühns K, Kunzmann V, Tony HP, et al. (1999) V γ 9/V δ 2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. *FEMS Immunol Med Microbiol* 25: 371–378.
58. Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, et al. (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR $\gamma\delta$ cells. *Eur J Immunol* 38: 2200–2209.
59. Mookerjee-Basu J, Vantourout P, Martinez LO, Perret B, Collet X, et al. (2010) F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for V γ 9V δ 2 T cells. *J Immunol* 184: 6920–6928.
60. Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N (2003) Requirement of species-specific interactions for the activation of human $\gamma\delta$ T cells by pamidronate. *J Immunol* 170: 3608–3613.
61. Sarikonda G, Wang H, Puan KJ, Liu XH, Lee HK, et al. (2008) Photoaffinity antigens for human $\gamma\delta$ T cells. *J Immunol* 181: 7738–7750.
62. Zhang Y, Song Y, Yin F, Broderick E, Siegel K, et al. (2006) Structural studies of V γ 2V δ 2 T cell phosphoantigens. *Chem Biol* 13: 985–992.
63. Boëdec A, Sicard H, Dessolin J, Herbet G, Ingoure S, et al. (2008) Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (*E*)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. *J Med Chem* 51: 1747–1754.
64. Altincicek B, Moll J, Campos N, Foerster G, Beck E, et al. (2001) Human $\gamma\delta$ T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis. *J Immunol* 166: 3655–3658.
65. Eberl M, Hintz M, Jamba Z, Beck E, Jomaa H, et al. (2004) *Mycoplasma penetrans* is capable of activating V γ 9/V δ 2 T cells while other human pathogenic mycoplasmas fail to do so. *Infect Immun* 72: 4881–4883.
66. Pietschmann K, Beetz S, Welte S, Martens I, Gruen J, et al. (2009) Toll-like receptor expression and function in subsets of human $\gamma\delta$ T lymphocytes. *Scand J Immunol* 70: 245–255.
67. Matsushima A, Ogura H, Fujita K, Koh T, Tanaka H, et al. (2004) Early activation of $\gamma\delta$ T lymphocytes in patients with severe systemic inflammatory response syndrome. *Shock* 22: 11–15.
68. Llewellyn MJ, Cohen J (2007) Tracking the microbes in sepsis: advancements in treatment bring challenges for microbial epidemiology. *Clin Infect Dis* 44: 1343–1348.
69. Blunden M, Zeitlin D, Ashman N, Fan SL (2007) Single UK centre experience on the treatment of PD peritonitis—antibiotic levels and outcomes. *Nephrol Dial Transplant* 22: 1714–1719.
70. Bunke CM, Brier ME, Golper TA (1997) Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. *Kidney Int* 52: 524–529.
71. Choi P, Nemati E, Banerjee A, Preston E, Levy J, et al. (2004) Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. *Am J Kidney Dis* 43: 103–111.
72. Kim DK, Yoo TH, Ryu DR, Xu ZG, Kim HJ, et al. (2004) Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. *Perit Dial Int* 24: 424–432.
73. Krishnan M, Thodis E, Ikonopoulou D, Vidgen E, Chu M, et al. (2002) Predictors of outcome following bacterial peritonitis in peritoneal dialysis. *Perit Dial Int* 22: 573–581.
74. Mujais S (2006) Microbiology and outcomes of peritonitis in North America. *Kidney Int* 70: S55–S62.
75. Szeto CC, Chow KM (2007) Gram-negative peritonitis - the Achilles heel of peritoneal dialysis? *Perit Dial Int* 27: S267–S271.
76. Troidle L, Gorban-Brennan N, Klinger A, Finkelstein F (1998) Differing outcomes of Gram-positive and Gram-negative peritonitis. *Am J Kidney Dis* 32: 623–628.
77. Fahim M, Hawley CM, McDonald SP, Brown FG, Rosman JB, et al. (2010) Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. *Am J Kidney Dis* 55: 690–697.
78. Rohmer M, Grosdemange-Billiard C, Seemann M, Trisch D (2004) Isoprenoid biosynthesis as a novel target for antibacterial and antiparasitic drugs. *Curr Opin Investig Drugs* 5: 154–162.
79. Oldfield E (2010) Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. *Acc Chem Res* 43: 1216–1226.
80. Feurle J, Espinosa E, Eckstein S, Pont F, Kunzmann V, et al. (2002) *Escherichia coli* produces phosphoantigens activating human $\gamma\delta$ T cells. *J Biol Chem* 277: 148–154.
81. Puan KJ, Jin C, Wang H, Sarikonda G, Raker AM, et al. (2007) Preferential recognition of a microbial metabolite by human V γ 2V δ 2 T cells. *Int Immunol* 19: 657–673.
82. Belmant C, Espinosa E, Halary F, Tang Y, Peyrat MA, et al. (2000) A chemical basis for selective recognition of nonpeptide antigens by human delta T cells. *FASEB J* 14: 1669–1670.
83. Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, et al. (2006) Safety and efficacy of affinity-purified, anti-tumor necrosis factor- α , ovine fab for injection (CytoFab) in severe sepsis. *Crit Care Med* 34: 2271–81.
84. Clinical and Laboratory Standards Institute (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - eighth edition. Approved standard: M07-A8. Wayne Pennsylvania: CLSI.
85. Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement: M100-S20. Wayne, Pennsylvania: CLSI.
86. Ganz T, Lehrer RI (1995) Defensins. *Pharmacol Ther* 66: 191–205.
87. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, et al. (1989) Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. *J Clin Invest* 83: 865–875.